In the CLL cohort studied here, although approximately 1/3 patients had higher PARP activity than HV, median PARP activity was not significantly different in CLL cases, largely due to the huge variation in activity in the cohort. The gene discussed is PARP1; the disease is B-cell chronic lymphocytic leukemia.